More than three months after a COVID-19 prevention drug was granted a green light from government officials, why is the immune-compromised population scrambling to get it?
At least 7 million immunocompromised people could benefit from the monoclonal antibody injections designed to prevent covid-19. The government says it has enough doses for a fraction of those in need ― and it doesn’t have the money to buy more.
As immunocompromised people across the country work to get Evusheld, a potentially lifesaving covid therapy, several hundred providers of the injections were removed from a federal dataset on Wednesday night, making the therapy even harder to locate.
On the second anniversary of the WHO declaring COVID to be global pandemic, doctors reflected on the evolution of treatments and the wide variety that are accessible.